Cargando…

Drug–Drug Interactions of 257 Antineoplastic and Supportive Care Agents With 7 Anticoagulants: A Comprehensive Review of Interactions and Mechanisms

Data on drug–drug interactions (DDI) of antineoplastic drugs with anticoagulants is scarce. We aim to evaluate factors associated with DDI of antineoplastic and supportive care drugs with anticoagulants resulting in modification of pharmacokinetics of these last mentioned. A literature review on DDI...

Descripción completa

Detalles Bibliográficos
Autores principales: Peixoto de Miranda, Érique José F., Takahashi, Thamy, Iwamoto, Felipe, Yamashiro, Suzete, Samano, Eliana, Macedo, Ariane Vieira Scarlatelli, Ramacciotti, Eduardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466894/
https://www.ncbi.nlm.nih.gov/pubmed/32862668
http://dx.doi.org/10.1177/1076029620936325
_version_ 1783577912014798848
author Peixoto de Miranda, Érique José F.
Takahashi, Thamy
Iwamoto, Felipe
Yamashiro, Suzete
Samano, Eliana
Macedo, Ariane Vieira Scarlatelli
Ramacciotti, Eduardo
author_facet Peixoto de Miranda, Érique José F.
Takahashi, Thamy
Iwamoto, Felipe
Yamashiro, Suzete
Samano, Eliana
Macedo, Ariane Vieira Scarlatelli
Ramacciotti, Eduardo
author_sort Peixoto de Miranda, Érique José F.
collection PubMed
description Data on drug–drug interactions (DDI) of antineoplastic drugs with anticoagulants is scarce. We aim to evaluate factors associated with DDI of antineoplastic and supportive care drugs with anticoagulants resulting in modification of pharmacokinetics of these last mentioned. A literature review on DDI databases and summaries of products characteristics (SmPC) was done. Drug–drug interactions of 257 antineoplastic and supportive care drugs with direct oral anticoagulants (DOACs), warfarin, enoxaparin, or fondaparinux were categorized as no clinically significant expected DDI, potentially weak DDI, potentially clinically significant DDI, and recommendation against coadministration. Logistic regression models were performed to analyze the association between the dependent variable potentially clinically significant interaction/recommendation against coadministration and the mechanisms of DDI. Of the 1799 associations, 84.4% were absence of DDI, 3.6% potentially weak DDI, 10.2% potentially clinically relevant DDI, and 2.0% recommendation against coadministration. Warfarin has higher DDI potential than other anticoagulants. Enoxaparin and fondaparinux have fewer DDI than others. There was no difference between DOACs. Drug–drug interactions with apixaban and rivaroxaban was independently associated with the absence of CYP3A4 competition, P-glycoprotein inhibition, CYP3A4 induction, and drug class of tyrosine kinase inhibitors. Drug–drug interactions with dabigatran and edoxaban was associated with inhibition of P-glycoprotein and tyrosine kinase inhibitors. Warfarin, induction of CYP3A4, and inhibition of CYP2C9. Enoxaparin and fondaparinux, only tyrosine kinase inhibitors. Direct oral anticoagulants did not differ regarding DDI with antineoplastic agents. Warfarin presented more DDI than other anticoagulants. P-glycoprotein inhibition and CYP3A4 induction were independently associated with DDI of antineoplastic agents with DOACs.
format Online
Article
Text
id pubmed-7466894
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-74668942020-09-16 Drug–Drug Interactions of 257 Antineoplastic and Supportive Care Agents With 7 Anticoagulants: A Comprehensive Review of Interactions and Mechanisms Peixoto de Miranda, Érique José F. Takahashi, Thamy Iwamoto, Felipe Yamashiro, Suzete Samano, Eliana Macedo, Ariane Vieira Scarlatelli Ramacciotti, Eduardo Clin Appl Thromb Hemost Original Article Data on drug–drug interactions (DDI) of antineoplastic drugs with anticoagulants is scarce. We aim to evaluate factors associated with DDI of antineoplastic and supportive care drugs with anticoagulants resulting in modification of pharmacokinetics of these last mentioned. A literature review on DDI databases and summaries of products characteristics (SmPC) was done. Drug–drug interactions of 257 antineoplastic and supportive care drugs with direct oral anticoagulants (DOACs), warfarin, enoxaparin, or fondaparinux were categorized as no clinically significant expected DDI, potentially weak DDI, potentially clinically significant DDI, and recommendation against coadministration. Logistic regression models were performed to analyze the association between the dependent variable potentially clinically significant interaction/recommendation against coadministration and the mechanisms of DDI. Of the 1799 associations, 84.4% were absence of DDI, 3.6% potentially weak DDI, 10.2% potentially clinically relevant DDI, and 2.0% recommendation against coadministration. Warfarin has higher DDI potential than other anticoagulants. Enoxaparin and fondaparinux have fewer DDI than others. There was no difference between DOACs. Drug–drug interactions with apixaban and rivaroxaban was independently associated with the absence of CYP3A4 competition, P-glycoprotein inhibition, CYP3A4 induction, and drug class of tyrosine kinase inhibitors. Drug–drug interactions with dabigatran and edoxaban was associated with inhibition of P-glycoprotein and tyrosine kinase inhibitors. Warfarin, induction of CYP3A4, and inhibition of CYP2C9. Enoxaparin and fondaparinux, only tyrosine kinase inhibitors. Direct oral anticoagulants did not differ regarding DDI with antineoplastic agents. Warfarin presented more DDI than other anticoagulants. P-glycoprotein inhibition and CYP3A4 induction were independently associated with DDI of antineoplastic agents with DOACs. SAGE Publications 2020-08-31 /pmc/articles/PMC7466894/ /pubmed/32862668 http://dx.doi.org/10.1177/1076029620936325 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Peixoto de Miranda, Érique José F.
Takahashi, Thamy
Iwamoto, Felipe
Yamashiro, Suzete
Samano, Eliana
Macedo, Ariane Vieira Scarlatelli
Ramacciotti, Eduardo
Drug–Drug Interactions of 257 Antineoplastic and Supportive Care Agents With 7 Anticoagulants: A Comprehensive Review of Interactions and Mechanisms
title Drug–Drug Interactions of 257 Antineoplastic and Supportive Care Agents With 7 Anticoagulants: A Comprehensive Review of Interactions and Mechanisms
title_full Drug–Drug Interactions of 257 Antineoplastic and Supportive Care Agents With 7 Anticoagulants: A Comprehensive Review of Interactions and Mechanisms
title_fullStr Drug–Drug Interactions of 257 Antineoplastic and Supportive Care Agents With 7 Anticoagulants: A Comprehensive Review of Interactions and Mechanisms
title_full_unstemmed Drug–Drug Interactions of 257 Antineoplastic and Supportive Care Agents With 7 Anticoagulants: A Comprehensive Review of Interactions and Mechanisms
title_short Drug–Drug Interactions of 257 Antineoplastic and Supportive Care Agents With 7 Anticoagulants: A Comprehensive Review of Interactions and Mechanisms
title_sort drug–drug interactions of 257 antineoplastic and supportive care agents with 7 anticoagulants: a comprehensive review of interactions and mechanisms
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466894/
https://www.ncbi.nlm.nih.gov/pubmed/32862668
http://dx.doi.org/10.1177/1076029620936325
work_keys_str_mv AT peixotodemirandaeriquejosef drugdruginteractionsof257antineoplasticandsupportivecareagentswith7anticoagulantsacomprehensivereviewofinteractionsandmechanisms
AT takahashithamy drugdruginteractionsof257antineoplasticandsupportivecareagentswith7anticoagulantsacomprehensivereviewofinteractionsandmechanisms
AT iwamotofelipe drugdruginteractionsof257antineoplasticandsupportivecareagentswith7anticoagulantsacomprehensivereviewofinteractionsandmechanisms
AT yamashirosuzete drugdruginteractionsof257antineoplasticandsupportivecareagentswith7anticoagulantsacomprehensivereviewofinteractionsandmechanisms
AT samanoeliana drugdruginteractionsof257antineoplasticandsupportivecareagentswith7anticoagulantsacomprehensivereviewofinteractionsandmechanisms
AT macedoarianevieirascarlatelli drugdruginteractionsof257antineoplasticandsupportivecareagentswith7anticoagulantsacomprehensivereviewofinteractionsandmechanisms
AT ramacciottieduardo drugdruginteractionsof257antineoplasticandsupportivecareagentswith7anticoagulantsacomprehensivereviewofinteractionsandmechanisms